161712-75-0

Basic information

• Product Name: 3,4-DIFLUOROHYDROCINNAMIC ACID
• Synonyms: 3-(3,4-DIFLUOROPHENYL)-PROPIONIC ACID;3,4-DIFLUOROHYDROCINNAMIC ACID;3-(3,4-Difluorophenyl)propanoic acid;3,4-Difluorohydrociamicacid;3,4-Difluorobenzenepropanoic acid;3,4-Difluorohydrocinnamic acid, 3-(3,4-Difluorophenyl)propionic acid;3,4-Difluorohydrocinnamic acid 97%;Benzenepropanoicacid,3,4-difluoro
• CAS NO: 161712-75-0
• Molecular Formula: C₉H₈F₂O₂
• Molecular Weight: 186.16
• Product Categories: Aromatic Cinnamic Acids, Esters and Derivatives
• Mol File: 161712-75-0.mol

Chemical Properties

• Melting Point: 49-53 °C(lit.)
• Boiling Point: 278℃
• Flash Point: 122℃
• Appearance: /
• Density: 1.312
• Vapor Pressure: 0.00213mmHg at 25°C
• Refractive Index: 1.503
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 3,4-DIFLUOROHYDROCINNAMIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-DIFLUOROHYDROCINNAMIC ACID(161712-75-0)
• EPA Substance Registry System: 3,4-DIFLUOROHYDROCINNAMIC ACID(161712-75-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 161712-75-0(Hazardous Substances Data)

Usage

Chemical Properties

White powder

InChI:InChI=1/C9H8F2O2/c10-7-3-1-6(5-8(7)11)2-4-9(12)13/h1,3,5H,2,4H2,(H,12,13)

Upstream product

• 375368-92-6 ethyl 3-(3,4-difluorophenyl)acrylate 
• 34036-07-2 3,4 difluorobenzaldehyde 
• 803687-25-4 ethyl 3-(3,4-difluorophenyl)propanoate 
• 152152-17-5 3-(3,4-difluorophenyl)-2-propenoic acid 

Downstream Products

• 161712-76-1 3-(3,4-difluorophenyl)propanoyl chloride 
• 161712-77-2 5,6-difluoroindan-1-one 
• 301185-99-9 3,4-difluorobenzenepropanol 
• 1613696-30-2 2-[2-(3,4-difluorophenyl)ethyl]-5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[2-(morpholin-4-yl)ethyl]-1H-benzimidazole 
• 815618-48-5 4-(R)-benzyl-3-[3-(3,4-difluorophenyl)propionyl]oxazolidine-2-one 
• 1008798-43-3 N-[2-(3-{4-[(benzylethylamino)methyl]phenyl}-2-oxo-2H-chromen-6-yloxy)ethyl]-3-(3,4-difluorophenyl)propionamide 
• 1008798-47-7 N-[2-(3-{4-[(benzylethylamin)methyl]phenyl}-2-oxo-2H-chromen-7-yloxy)ethyl]-3-(3,4-difluorophenyl)propionamide 
• 803687-25-4 ethyl 3-(3,4-difluorophenyl)propanoate 
• 881190-18-7 6,7-difluoroindanone 
• 459872-41-4 N-[3-(3,4-difluorophenyl)propyl]-N-methylamine 

Relevant articles and documents

Method for selective reduction α, β - unsaturated carbonyl compound carbon-carbon double bond (by machine translation)

The invention discloses a method for selectively reducing carbon-carbon double bonds in α and β - unsaturated carbonyl compounds, which comprises the following steps of adding α, β - unsaturated carbonyl compounds shown in formula (I) in an electrolysis system and reducing α and β - unsaturated carbonyl compounds with carbonyl-conjugated carbon-carbon double bonds through an electrochemical cathodic reduction reaction. Compared with the reported method, the method disclosed by the invention does not use a metal catalyst and an external oxidant; and the reaction raw material and the electrolyte are low in price, nontoxic and tasteless, simple and convenient in post-treatment. (by machine translation)

PYRIDOPYRAZINE AND PYRIDOTRIAZINE INHIBITORS OF INFLUENZA VIRUS REPLICATION

Provided herein are compounds that can inhibit the replication of influenza viruses, reduce the amount of influenza viruses, and/or treat influenza. (I)

P2X4 RECEPTOR MODULATING COMPOUNDS

Provided herein are P2X4 receptor modulating compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, including but not limited to, chronic pain, neuropathy, inflammatory diseases and central nervous system disorders.

Bicyclic cyclohexylamines and their use as nmda receptor antagonists

Described are bicycle-substituted cyclohexylamines of Formula (I) and their pharmaceutically acceptable salts thereof. The compounds are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, cerebral ischemia, cardiac arrest, stroke, and Parkinson's specification. disease. The substituents are defined in the specification.